All In Biotech

BLA 125553 · Sandoz INC

Zarxio

Filgrastim-Sndz · Injection · Leukocyte Growth Factor

Last checked: Nov 20, 2026Latest source record: Aug 21, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Mar 6, 2015

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,650

302 Phase 3, 127 recruiting

FAERS reports

3,331

1,898 serious, 751 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 29, 2025.

ZARXIO is a leukocyte growth factor indicated to • Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti‑cancer drugs associated with a significant incidence of severe neutropenia with fever ( 1.1 ) • Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) ( 1.2 ) • Reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT) ( 1.3 ) • Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis ( 1.4 ) • Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia ( 1.5 ) • Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome) ( 1.6 ) 1.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy ZARXIO is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever [see Clinical Studies ( 14.1 )] . 1.2 Patients with Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy ZARXIO is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy...

Mechanism: Colony-stimulating factors are glycoproteins which act on hematopoietic cells by binding to specific cell surface receptors and stimulating proliferation‚ differentiation commitment‚ and some end-cell functional activation. Endogenous G-CSF is a lineage-specific colony-stimulating factor that is produced by monocytes‚ fibroblasts, and endothelial cells. G-CSF regulates the production of neutrophils within the bone marrow and affects neutrophil progenitor proliferation‚ differentiation, and selected end-cell functions (including enhanced phagocytic ability‚ priming of the cellular metabolism...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • ZARXIO · FILGRASTIM-SNDZ 480 mcg/0.8 mL · INJECTABLE, INJECTION · Prescription
  • ZARXIO · FILGRASTIM-SNDZ 300 mcg/0.5 mL · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Filgrastim" as an intervention, any sponsor and status, largest first.

All 1,650 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death635
  • fatigue174
  • white blood cell count decreased169
  • diarrhoea136
  • nausea116
  • off label use95
  • hospitalisation92
  • pyrexia91
  • neutropenia86
  • platelet count decreased76
  • asthenia75
  • bone pain74

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20151
201656
2017123
2018263
2019372
2020532
2021706
2022379
2023337
2024270
2025171
2026121

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zarxio (Filgrastim-Sndz)

2024 spending

$48.3M

Beneficiaries

9,326

24,638 claims

Per beneficiary

$5,179

$526.76 per unit

View as table
YearSpending
2020$47,512,862
2021$48,265,883
2022$49,541,222
2023$47,452,545
2024$48,295,463

Part B: Zarxio (Filgrastim-Sndz) · HCPCS Q5101

2024 spending

$9.4M

Beneficiaries

12,437

57,172 claims

Per beneficiary

$753

2024 ASP limit $0.34 per unit

View as table
YearSpending
2020$28,723,237
2021$18,684,232
2022$13,756,899
2023$3,244,055
2024$9,367,245

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 742 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.